Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
|Videos|May 16, 2014
Personalized Therapies in Advanced Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.
Advertisement
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.
Clinical Pearls:
- Physicians have known for some time that there are molecular targets that are amenable to therapy
- Now that the entire genome can be sequenced, physicians are understanding more about mutations in breast cancer
- Upon sequencing the tumors of many patients with breast cancer, physicians are finding that no two tumors are the same
- New mutations may be picked up after analyzing a patient’s tumor after treatment
Advertisement
Related to this article
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5